Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Total Rare Rare [Member] Rare Title of 12(b) Security Title of 12(b) Security Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Document Fiscal Year Focus Document Fiscal Year Focus Roche Roche [Member] Roche Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] Segment Reporting [Abstract] Common stock, $0.01 par value per share, 250,000 shares authorized; 133,734 shares issued and outstanding as of June 30, 2026; 132,376 shares issued and outstanding as of December 31, 2025 Common Stock, Value, Issued Depreciation and amortization Depreciation, Amortization and Accretion, Net Loss contingencies accrued Loss Contingency Accrual Line of Credit Line of Credit [Member] Restatement Determination Date Restatement Determination Date Number of partnered products Number Of Partnered Products Number Of Partnered Products Debt instrument, conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] HELIOS-B Phase 3 Clinical Trial HELIOS-B Phase 3 Clinical Trial [Member] HELIOS-B Phase 3 Clinical Trial Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Schedule of Reconciliation of Cash, Cash Equivalents And Restricted Cash Schedule Of Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Table Text Block] Statement of reconciliation of cash, cash equivalents and restricted cash. Convertible Senior Notes Due 2027 Convertible Senior Notes Due 2027 [Member] Convertible Senior Notes Due 2027 Amount received Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Long-term inventory Inventory, Noncurrent Research And Development Expense [Domain] Research And Development Expense [Domain] Research And Development Expense [Domain] ONPATTRO ONPATTRO [Member] ONPATTRO Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Debt Conversion Terms One Debt Conversion Terms One [Member] Debt Conversion Terms One Closing costs Royalty Liability, Closing Costs Royalty Liability, Closing Costs Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Foreign currency translation (losses) gains Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Financial assets Assets, Fair Value Disclosure [Abstract] Purchase of capped calls related to —% Convertible Senior Notes due 2028 Adjustments To Additional Paid In Capital, Option Contract Indexed To Equity Adjustments To Additional Paid In Capital, Option Contract Indexed To Equity Sinking fund payment Debt Instrument, Sinking Fund Payment Selling, General and Administrative Expense [Axis] Selling, General and Administrative Expense [Axis] Selling, General and Administrative Expense Weighted-average common shares - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Arrangements and Non-arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Number of Reportable Segments Number of Reportable Segments Credit or payments made during the period for current year sales Valuation Allowances And Reserves Sales Credit Payment Current Valuation Allowances And Reserves Sales Credit Payment Current Total current liabilities Liabilities, Current Convertible debt Convertible Debt, Noncurrent Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Before Tax, Including Cash Equivalents Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Before Tax, Including Cash Equivalents Statements of Comprehensive Income (Loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Entity Address, City or Town Entity Address, City or Town Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Net product revenues Product [Member] Schedule of Balances and Activity in Each Product Revenue Allowance and Reserve Category Summary Of Product Revenue Allowance And Reserve Categories Table [Table Text Block] Summary Of Product Revenue Allowance And Reserve Categories Table Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Number of separate programs Number Of Separate Programs Number Of Separate Programs Interest expense Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Interest Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Interest Significant Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Other (expense) income: Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Aggregate principal amount Line of Credit Facility, Maximum Borrowing Capacity Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Loss related to convertible debt Induced Conversion of Convertible Debt Expense License License [Member] United States UNITED STATES Capitalized stock-based compensation costs Share-Based Payment Arrangement, Amount Capitalized Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Capital expenditures included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Deferred revenue Increase (Decrease) in Contract with Customer, Liability Schedule of Expenses by Segment Segment Reporting [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Total other comprehensive (loss) income Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Royalties payable, percent Collaborative Arrangement, Royalties Payable, Percent Collaborative Arrangement, Royalties Payable, Percent Schedule of Fair Value, Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Long term debt outstanding Long-Term Debt Development costs, percentage responsible Development Costs, Percent Responsible Development Costs, Percent Responsible Supplemental disclosure of noncash investing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Aggregate principal amount Debt Instrument, Face Amount Operating costs and expenses: Costs and Expenses [Abstract] Security Exchange Name Security Exchange Name Effective interest rate (as percent) Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Net income (loss), for use in diluted income per share Net Income (Loss) Attributable to Parent, Diluted Royalty rate Royalty Rate Potential maximum royalty percentage that will received for sales completed by collaboration partner. Issuance of common stock under equity plans Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture Roche License Obligation License Obligation [Member] License Obligation Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Operating lease liabilities Operating Lease, Liability, Current Obligations Obligations [Member] Other Other Collaborations [Member] Other collaboration. Vutrisiran and ALN-AGT Vutrisiran and Zilebesiran [Member] Vutrisiran and Zilebesiran NET INCOME (LOSS) PER COMMON SHARE Earnings Per Share [Text Block] Proceeds from maturity of restricted and other investments Proceeds from Sale of Restricted Investments Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Earnings Per Share [Abstract] Sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Including Cash Equivalents Debt Securities, Available-for-Sale, Amortized Cost, Including Cash Equivalents Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] OXLUMO OXLUMO [Member] OXLUMO Total liabilities Liabilities Trading Symbol Trading Symbol Geographical Geographical [Domain] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Zilebesrian Zilebesrian [Member] Zilebesrian Cap price (in dollars per share) Option Indexed to Issuer's Equity, Strike Price Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Funding At Program Initiation Funding At Program Initiation [Member] Funding at program initiation. Company Selected Measure Name Company Selected Measure Name Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Amounts reclassified from accumulated other comprehensive loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Number of cardiometabolic programs Number Of Cardiometabolic Programs Number Of Cardiometabolic Programs Purchase price Payments to Acquire Other Investments Defined Benefit Pension Plans, Net of Tax Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Long term debt outstanding Long-Term Debt, Gross Actual reimbursement of transactional price (as percent) Revenue Recognition, Percentage of Actual Reimbursement Revenue Recognition, Percentage of Actual Reimbursement Interest expense Royalty Liability, Interest Expense Including Amortization Of Closing Costs Royalty Liability, Interest Expense Including Amortization Of Closing Costs Credit Facility [Domain] Credit Facility [Domain] Related Party Transactions [Abstract] Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Single Reportable Segment Single Reportable Segment [Member] Single Reportable Segment Debt Instrument, Convertible Terms of Conversion [Axis] Debt Instrument, Convertible Terms of Conversion [Axis] Debt Instrument, Convertible Terms of Conversion Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Weighted-average common shares - diluted (in shares) Weighted-average common shares - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Commercial paper Commercial Paper [Member] U.S. treasury securities US Treasury Securities [Member] Type of Arrangement and Non-arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Net revenues from collaborations Collaborations Collaborations [Member] Collaborations Restricted investments Restricted Investments, Noncurrent Award Timing Predetermined Award Timing Predetermined [Flag] Consideration received Collaborative Arrangement, Consideration Received Collaborative Arrangement, Consideration Received Issuance of letters of credit Letters of Credit Outstanding, Amount Schedule of Available-for-sale Securities [Line Items] Debt Securities, Available-for-Sale [Line Items] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Other Incentives and Allowances Other Incentives And Allowances [Member] Other Incentives And Allowances Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Debt instrument conversion ratio Debt Instrument, Convertible, Conversion Ratio Options, RSUs, and ESPP (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Global Strategic Collaboration Global Strategic Collaboration [Member] Global strategic collaboration. Cap price (in dollars per share) Derivative, Cap Price All Executive Categories All Executive Categories [Member] Loss on Investment in Joint Venture Accumulated Loss On Investment In Joint Venture [Member] Accumulated loss on investment in joint venture. Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Fair value of long-term debt Long-Term Debt, Fair Value Development Milestone Development Milestone [Member] Development Milestone Antidilutive Securities [Axis] Antidilutive Securities [Axis] Scenario [Domain] Scenario [Domain] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Debt Conversion Terms Three Debt Conversion Terms Three [Member] Debt Conversion Terms Three C5 Monotherapy Obligation C5 Monotherapy Obligation [Member] C5 Co-Co obligation. Schedule of Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Disclosure [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Fixed consideration Fixed Consideration Fixed Consideration Royalty revenue Royalty [Member] SEGMENT INFORMATION Segment Reporting [Text Block] Outstanding borrowings Long-Term Line of Credit Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Credit or payments made during the period for prior years’ sales Valuation Allowances And Reserves Sales Credit Payment Prior Valuation Allowances And Reserves Sales Credit Payment Prior Schedule of Deferred Revenue Activity Disaggregation of Revenue [Table Text Block] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement Location Location, Statement of Income, Balance [Axis] Restricted cash (money market funds) Restricted Cash and Cash Equivalent Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value Total Debt Securities, Available-for-Sale, Including Cash Equivalents Debt Securities, Available-for-Sale, Including Cash Equivalents Cash equivalents Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Expected royalty interest payments Expected Royalty Interest Payments Expected Royalty Interest Payments Vutrisiran Vutrisiran [Member] Vutrisiran Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Regeneron Technology Transfer Obligation Regeneron Technology Transfer Obligation [Member] Regeneron Technology Transfer Obligation Convertible Senior Notes Due 2027, Additional Amount Convertible Senior Notes Due 2027, Additional Amount [Member] Convertible Senior Notes Due 2027, Additional Amount Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Exercise Price Award Exercise Price Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Segment Reporting [Line Items] Segment Reporting [Line Items] Fixed payment, term (in years) Collaborative Arrangement, Fixed Payment, Term Collaborative Arrangement, Fixed Payment, Term Document Quarterly Report Document Quarterly Report Selling, General and Administrative Expense [Domain] Selling, General and Administrative Expense [Domain] Selling, General and Administrative Expense [Domain] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] Europe Europe [Member] CONVERTIBLE DEBT AND OTHER FINANCING Debt Disclosure [Text Block] Repayment of liabilities related to the sale of future royalties and development funding Repayment Of Liabilities Related To The Sale Of Future Royalties And Development Funding Repayment Of Liabilities Related To The Sale Of Future Royalties And Development Funding Scenario [Axis] Scenario [Axis] Repayments of long-term debt Repayments of Long-Term Debt Debt issuance costs Debt Issuance Costs, Net Proceeds from liabilities related to the sale of future royalties and development funding Proceeds From Sale Of Royalties Interest Proceeds From Sale Of Royalties Interest Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Total operating costs and expenses Costs and Expenses Adoption Date Trading Arrangement Adoption Date Interest rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Counterparty Name Counterparty Name [Domain] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Total other expense, net Nonoperating Income (Expense) Cost of collaborations and royalties Cost Of Collaboration Manufacturing And Royalties Cost Of Collaboration Manufacturing And Royalties ASSETS Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Insider Trading Policies and Procedures [Line Items] Other financing activities Proceeds from (Payment for) Other Financing Activity Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Total TTR TTR [Member] TTR Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Deferred income taxes Deferred Income Tax Expense (Benefit) Selling, general and administrative Total selling, general and administrative expense Selling, General and Administrative Expense OTHER BALANCE SHEET DETAILS Supplemental Balance Sheet Disclosures [Text Block] Profit and loss sharing percentage Profit and Loss Sharing, Percent Profit and Loss Sharing, Percent Letter of Credit Letter of Credit [Member] AMVUTTRA Amvuttra [Member] Amvuttra COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Number of reporting segments Number of Operating Segments Anti-dilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Common Share Equivalents Excluded from the Calculation of Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Roche Development Services Obligation Development Services Obligation [Member] Development Services Obligation Inceptive Nucleics, Inc Inceptive Nucleics, Inc [Member] Inceptive Nucleics, Inc Entity Central Index Key Entity Central Index Key Additional paid-in capital Additional Paid in Capital, Common Stock All Adjustments to Compensation All Adjustments to Compensation [Member] Other Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Fair value of liability Royalty Liability, Fair Value Royalty Liability, Fair Value Income Statement [Abstract] Income Statement [Abstract] Stockholders' equity: Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] LIABILITIES RELATED TO THE SALE OF FUTURE ROYALTIES AND DEVELOPMENT FUNDING Liability Related To The Sale Of Future Royalties And Development Funding [Text Block] Liability Related To The Sale Of Future Royalties And Development Funding Deferred tax assets Deferred Income Tax Assets, Net Schedule of Allocated Transaction Price Based on Accounting Guidance Schedule of Allocated Transaction Price [Table Text Block] Schedule of Allocated Transaction Price Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Leverage ratio Debt Instrument, Basis Spread on Variable Rate Royalty Liability Rollforward [Abstract] Royalty Liability Rollforward [Abstract] Royalty Liability Rollforward Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax, Including Cash Equivalents Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax, Including Cash Equivalents City Area Code City Area Code Variable Rate [Domain] Variable Rate [Domain] Restricted stock units, inclusive of performance-based restricted stock units Restricted stock units, inclusive of performance-based restricted stock units Restricted Stock [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Net revenues from collaborations Net revenues from collaborations Collaborative Arrangement [Member] Maximum percentage of royalty payments Percentage Of Maximum Royalty Payments Percentage of maximum royalty payments. Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Name Forgone Recovery, Individual Name Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Statement [Line Items] Statement [Line Items] Total assets Assets Upfront payment Collaborative Arrangement, Upfront Payment Collaborative Arrangement, Upfront Payment Call Option Call Option [Member] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Convertible debt Convertible Debt [Member] Defined benefit pension plans, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Interest expense Interest Expense, Nonoperating STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Other comprehensive income before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent NATURE OF BUSINESS Nature of Operations [Text Block] PEO PEO [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Other liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercise of common stock options, net of tax withholdings (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Development milestone payable Collaborative Arrangement, Milestone Payable Collaborative Arrangement, Milestone Payable Contract with customer liability revenue recognized Contract with Customer, Liability, Revenue Recognized Realized and unrealized loss on marketable equity securities Equity Securities, FV-NI, Gain (Loss) Accumulated Deficit Retained Earnings [Member] Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Revolving Credit Facility Revolving Credit Facility [Member] Money market funds Money Market Funds [Member] Unrealized Gains (Losses) from Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Vir Biotechnology, Inc. Vir Biotechnology, Inc. [Member] Vir Biotechnology, Inc. Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Unrealized (losses) gains on marketable securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Schedule of Fair Value of Marketable Debt Securities Fair Value, by Balance Sheet Grouping [Table Text Block] Corporate notes Corporate Debt Securities [Member] Net income (loss) per common share — diluted (in dollars per share) Net income (loss) per common share—diluted (in dollars per share) Earnings Per Share, Diluted Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Regeneron Pharmaceuticals Regeneron Pharmaceuticals Incorporation [Member] Regeneron Pharmaceuticals, Incorporation. Schedule of Royalty Liability Schedule Of Royalty Liability [Table Text Block] Schedule Of Royalty Liability Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Liabilities related to the sale of future royalties and development funding Royalty And Development Funding Liability, Current Royalty And Development Funding Liability, Current Research and development Total research and development expense Research and Development Expense Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Total revenues Revenue Recognized Revenue from Contract with Customer, Excluding Assessed Tax Property, plant and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Royalty and development funding liability, fair value Royalty And Development Funding Liability, Fair Value Royalty And Development Funding Liability, Fair Value Commitment fee on the unused portion of leverage ratio Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Financial Instruments [Domain] Financial Instruments [Domain] Total stock-based compensation charges Share-Based Payment Arrangement, Expensed and Capitalized, Amount Other license programs Other License Programs [Member] Other License Programs Exercise of common stock options, net of tax withholdings Stock Issued During Period, Value, Stock Options Exercised Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount NET PRODUCT REVENUES Revenue from Contract with Customer [Text Block] Provision related to current year sales Valuation Allowances And Reserves Provision Related To Current Period Sales Valuation Allowances And Reserves Provision Related To Current Period Sales Proceeds from exercise of stock options and other types of equity, net Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Non-cash interest expense on liabilities related to the sale of future royalties and development funding Non-Cash Interest Expense On Sale Of Future Royalties Non-Cash Interest Expense On Sale Of Future Royalties Occupancy and all other costs Occupancy and All Other Costs [Member] Occupancy and All Other Costs Other investing activities Payment for (Proceeds from) Other Investing Activity Inventory Increase (Decrease) in Inventories Number of performance obligations Number of Performance Obligations Number of Performance Obligations Segment Reporting [Table] Segment Reporting [Table] Schedule of Marketable Debt Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 2028 Notes Convertible Senior Notes Due 2028 [Member] 2028 Notes Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Income (loss) from operations Operating Income (Loss) Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Current Fiscal Year End Date Current Fiscal Year End Date Funding At Lead Candidate Identification Funding At Lead Candidate Identification [Member] Funding at lead candidate identification. Maximum funding Collaborative Arrangement, Maximum Funding Collaborative Arrangement, Maximum Funding Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Issuance of common stock under equity plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Maximum royalties and commercial milestone payments upon potential product sale Maximum Royalties And Commercial Milestone Payments Upon Potential Product Sale Maximum royalties and commercial milestone payments upon potential product sale. Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Additional 2028 Notes Convertible Senior Notes Due 2028, Additional Amount [Member] Convertible Senior Notes Due 2028, Additional Amount Finished goods Inventory, Finished Goods, Gross BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION Business Description and Basis of Presentation [Text Block] Marketable debt securities Marketable debt securities Debt Securities, Available-for-Sale, Current Equity Components [Axis] Equity Components [Axis] Accounts receivable, net Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Cash paid for taxes Income Tax Paid, after Refund Received Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] ALN-AGT Phase 2 Clinical Trial ALN-AGT Phase 2 Clinical Trial [Member] ALN-AGT Phase 2 Clinical Trial Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Debt Conversion Terms Two Debt Conversion Terms Two [Member] Debt Conversion Terms Two Entity Interactive Data Current Entity Interactive Data Current Variable Rate [Axis] Variable Rate [Axis] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Amount paid Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Collaborative arrangement milestone payments, per collaboration project Collaborative Arrangement Milestone Payments, Per Collaboration Project Collaborative arrangement milestone payments. Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Revolving Credit Agreement Revolving Credit Agreement [Member] Revolving Credit Agreement MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Number of quarterly payments Collaborative Arrangement, Fixed Payment, Number Of Quarterly Payments Collaborative Arrangement, Fixed Payment, Number Of Quarterly Payments U.S. government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Potential proceeds from collaboration arrangement Potential Proceeds From Collaboration Arrangement Potential proceeds from collaboration arrangement. Other assets Other Assets, Noncurrent Document Type Document Type Debt, repurchased Debt Instrument, Repurchased Face Amount Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Accrued expenses Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Repurchase cost including accrued and unpaid interest Repayments of Convertible Debt Debt instrument, redemption price percentage Debt Instrument, Redemption Price, Percentage Initial 2028 Notes Convertible Senior Notes Due 2028, Initial Amount [Member] Convertible Senior Notes Due 2028, Initial Amount Blackstone Life Sciences Blackstone Life Sciences [Member] Blackstone Life Sciences Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Work in process Inventory, Work in Process, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Designated candidates, period after expiration of initial research term Collaboration Agreement, Designated Candidates, Period After Expiration Of Initial Research Term Collaboration Agreement, Designated Candidates, Period After Expiration Of Initial Research Term Consulting and professional services Consulting and Professional Services [Member] Consulting and Professional Services Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies (Note 12) Commitments and Contingencies Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Payments Royalty Liability, Payments Royalty Liability, Payments Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Counterparty Name Counterparty Name [Axis] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Total inventory Inventory, Current And Noncurrent Inventory, Current And Noncurrent Maximum additional milestone payments to be receive upon achievement of certain criteria Maximum Additional Milestone Payments To Be Receive Upon Achievement Of Certain Criteria Maximum additional milestone payments to be receive upon achievement of certain criteria. Adjustment for the elimination of interest expense on the convertible debt Interest On Convertible Debt, Adjustment Interest On Convertible Debt, Adjustment Schedule of Fair Value of Assets Measured on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Inventory Inventory, Net All Award Types Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Supplemental disclosure of cash flows: Supplemental Cash Flow Information [Abstract] Share price (in dollars per share) Share Price PEO Name PEO Name Percentage of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Collaborative arrangement, royalties and commercial milestones acquired by collaborator, percent Collaborative Arrangement, Royalties And Commercial Milestones Acquired By Collaborator, Percent Collaborative Arrangement, Royalties Acquired By Collaborator, Percent Geographical Geographical [Axis] Blackstone Group Inc. Blackstone Group Inc. [Member] Blackstone Group Inc. Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Schedule of Revenue from Collaborators Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Liability Class [Axis] Liability Class [Axis] Compensation and related Compensation and Related [Member] Compensation and Related MARKETABLE DEBT SECURITIES Investments In Marketable Debt Securities Disclosure [Text Block] Investments in marketable debt securities disclosure. Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Base Rate Base Rate [Member] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Liabilities related to the sale of future royalties and development funding, net of current portion Beginning balance Ending balance Royalty Liability, Noncurrent Royalty Liability, Noncurrent Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument [Axis] Debt Instrument [Axis] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Provision related to prior years’ sales Valuation Allowances And Reserves Provision Related To Prior Period Sales Valuation Allowances And Reserves Provision Related To Prior Period Sales Rest of World Non-US Or Europe [Member] Non-US Or Europe Research And Development Expense [Axis] Research And Development Expense [Axis] Research And Development Expense ALN-AGT Phase 3 Clinical Trial ALN-AGT Phase 3 Clinical Trial [Member] ALN-AGT Phase 3 Clinical Trial Employee stock purchase program Employee Stock [Member] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Net income (loss) per common share - basic (in dollars per share) Earnings Per Share, Basic Raw materials Inventory, Raw Materials, Gross Deferred revenue Contract liabilities included in deferred revenue Contract with Customer, Liability, Current Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Award Type Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable, net Net product revenue-related receivables Receivables included in accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Accumulated deficit Retained Earnings (Accumulated Deficit) Municipal securities Municipal Notes [Member] Royalties payable, term (in years) Collaborative Arrangement, Royalties Payable, Term Collaborative Arrangement, Royalties Payable, Term Product and Service [Axis] Product and Service [Axis] Trading days threshold Debt Instrument, Convertible, Threshold Trading Days Total restricted cash included in other assets Restricted Cash, Noncurrent Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Transaction price Transaction Price Transaction Price Common Stock Common Stock [Member] Number of marketed products Number Of Products With Marketing Approval Number Of Products With Marketing Approval Marketable debt securities Debt Securities, Available-for-Sale Interest rate Royalty Liability, Interest Rate Royalty Liability, Interest Rate Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Collaboration agreement, right to terminate, written advance notice period Collaboration Agreement, Right To Terminate, Written Advance Notice Period Collaboration Agreement, Right To Terminate, Written Advance Notice Period Covenant, leverage ratio, minimum Debt Instrument, Covenant, Liquidity Ratio, Minimum Debt Instrument, Covenant, Liquidity Ratio, Minimum Equity Awards Adjustments Equity Awards Adjustments [Member] Chargebacks and Rebates Chargebacks And Rebates [Member] Chargebacks And Rebates COLLABORATIONS Collaborative Arrangement Disclosure [Text Block] Roche Collaboration and License Agreement Roche Collaboration and License Agreement [Member] Roche Collaboration and License Agreement Total liabilities and stockholders' equity Liabilities and Equity Options to purchase common stock, inclusive of performance-based stock options Share-Based Payment Arrangement, Option [Member] Repurchase of 1.00% Convertible Senior Notes due 2027 Adjustments To Additional Paid In Capital, Repurchase Of Convertible Debt Adjustments To Additional Paid In Capital, Repurchase Of Convertible Debt Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Tabular List, Table Tabular List [Table Text Block] Schedule of Stock Based Compensation Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Other income (expense), net Other Nonoperating Income (Expense) Liquidity Liquidity Policy [Policy Text Block] Liquidity. Convertible debt (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Premium on capped call transactions Option Indexed to Issuer's Equity, Premium On Stock Price Option Indexed to Issuer's Equity, Premium On Stock Price Research Services Obligation Research Services Obligation [Member] Research services obligation. Initial conversion price, premium, percentage Debt Instrument, Convertible, Premium, Percentage Debt Instrument, Convertible, Premium, Percentage Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025 Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Collaboration agreement, initial research term Collaboration Agreement, Initial Research Term Collaboration Agreement, Initial Research Term Liability Related To The Sale Of Future Royalties [Line Items] Liability Related To The Sale Of Future Royalties [Line Items] Liability Related To The Sale Of Future Royalties [Line Items] Number of commercialized products Number Of Commercialized Products Number Of Commercialized Products Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] 2022 and 2025 Capped Call Transactions 2022 and 2025 Capped Call Transactions [Member] 2022 and 2025 Capped Call Transactions Credit Facility [Axis] Credit Facility [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total financial assets Assets, Fair Value Disclosure Name Measure Name Purchases of restricted and other investments Payments to Acquire Restricted Investments Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Debt Instrument, Convertible Terms of Conversion [Domain] Debt Instrument, Convertible Terms of Conversion [Domain] Debt Instrument, Convertible Terms of Conversion Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Covenant, interest coverage ratio, maximum Debt Instrument, Covenant, Interest Coverage Ratio, Maximum Debt Instrument, Covenant, Interest Coverage Ratio, Maximum Debt Instrument [Line Items] Debt Instrument [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Commercial milestones acquired by collaborator, percent Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalent Interest rate (as percent) Debt Instrument, Interest Rate During Period Company Selected Measure Amount Company Selected Measure Amount Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Entity Address, Address Line Two Entity Address, Address Line Two Roche Technology Transfer Obligation Technology Transfer Obligation [Member] Technology Transfer Obligation Liabilities related to the sale of future royalties and development funding, net of current portion Royalty And Development Funding Liability, Noncurrent Royalty And Development Funding Liability, Noncurrent Current assets: Assets, Current [Abstract] Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Operating lease right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Debt Conversion Terms Four Debt Conversion Terms Four [Member] Debt Conversion Terms Four Provision for income taxes Income Tax Expense (Benefit) GIVLAARI GIVLAARI [Member] GIVLAARI Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Cost of goods sold Cost of Product and Service Sold SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Award Timing Method Award Timing Method [Text Block] Other Product and Service, Other [Member] Basis of Presentation and Principles of Consolidation Consolidation, Policy [Policy Text Block] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forecast Forecast [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Net income (loss) Net income (loss) Net income (loss) Net income (loss), as reported Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Statement [Table] Statement [Table] 2022 Capped Call Transactions 2022 Capped Call Transactions [Member] 2022 Capped Call Transactions Restatement Determination Date: Restatement Determination Date [Axis] Schedule of Changes in Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Interest income Investment Income, Interest Clinical research and outside services Clinical Research and Outside Services [Member] Clinical Research and Outside Services Schedule of Deferred Revenue Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Consecutive trading days threshold Debt Instrument, Convertible, Threshold Consecutive Trading Days Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Revenues: Revenues [Abstract] C5 License Obligation C5 License Obligation [Member] C5 license obligation. Liability Related To The Sale Of Future Royalties [Table] Liability Related To The Sale Of Future Royalties [Table] Liability Related To The Sale Of Future Royalties Table Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Accounting Standards Update 2025-07 [Member]